Roth Capital reaffirms Regeneron (Nasdaq: REGN) at Buy with a price target of $520 following news that Phase II CAPELLA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Leerink Partners Reiterates Outperform on Regeneron (REGN) October 3, 2016 8:48 AM Leerink Positive on Ophthotech (OPHT) Amid Regeneron (REGN) FailureSeptember 30, 2016 8:58 AM Ophthotech Corp (OPHT) on Watch After Regeneron (REGN) Reports Eylea/Rinucumab Combo DataSeptember 30, 2016 8:05 AM Regeneron (REGN) Announces EYLEA Phase 2 CAPELLA Missed Primary Endpoint in Neovascular Age-Related Macular DegenerationSeptember 30, 2016 7:01 AM Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular DegenerationSeptember 30, 2016 7:00 AM